578.55↑10.90 (1.92%)
03:52 PM,29th Sep 2023576.45↑3.55 (0.62%)
04:01 PM,29th Sep 2023BSE : 524394
NSE : VIMTALABS
Sector : Others
ISIN Code : INE579C01029
Last Updated: Sep 29 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 1281 |
Turnover (₹ Cr) | 0.25 |
Volume (Shares) | 43324 |
Face Value | 2 |
52-WK High | 623.15 |
52-WK High Date | 25 Aug 2023 |
52-WK Low | 291.85 |
52-WK Low Date | 20 Mar 2023 |
All Time High | 623.15 |
All Time High Date | 25 Aug 2023 |
All Time Low | 12.55 |
All Time Low Date | 13 Mar 2009 |
Vimta Labs Ltd. established in 1984 is India's most comprehensive contract research and testing organization providing wide range of services to pharmaceutical biopharmaceutical food consumer goods electronic electrical agrochemical healthcare medical device and many other industries. Broadly these services include: Drug discovery development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP) clinical research central lab and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers processors farmers retailers traders exporters regulators; Clinical diagnostics services to patients clinicians hospitals and Environmental regulatory services such as impact assessments and post project monitoring to industries such as infrastructure power cement oil & gas mining etc. The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994.In 1997 the Company entered into a Joint Venture with Russian Centre for Testing and Certification ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia.During 2002 the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials.The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park Genome Valley Turkapally Village Shamirpet Mandal Ranga Reddy Dist. The project is expected to commence from September 2005.During the year 2006-07 the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park Genome Valley Hyderabad which started commercial operations from September 2006.During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited on 04th March 2020 making Emtac a wholly owned subsidiary of the Company.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 1281 |
EPS - TTM (₹) [S] | 21.17 |
P/E Ratio (X) [S] | 4.57 |
Face Value (₹) | 2 |
Latest Dividend (%) | 100.00 |
Latest Dividend Date | 21 Jun 2023 |
Dividend Yield (%) | 0.35 |
Book Value Share (₹) [S] | 126.69 |
P/B Ratio (₹) [S] | 4.57 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Quant Small Cap Fund - (G) | 19.08 | 330152 | 0.24 |
Quant Small Cap Fund - (IDCW) | 19.08 | 330152 | 0.24 |
Quant Small Cap Fund - Direct (G) | 19.08 | 330152 | 0.24 |
Quant Small Cap Fund - Direct (IDCW) | 19.08 | 330152 | 0.24 |
Motilal Oswal S&P BSE Healthcare ETF | 0.00 | 74 | 0.05 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 565.15 580.00 |
Week Low/High | 535.30 580.00 |
Month Low/High | 531.65 605.00 |
Year Low/High | 291.85 623.00 |
All time Low/High | 0.20 623.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 7.63% | 7.32% | -0.27 | -0.18% |
1 Month | 0.16% | 0.21% | 1.16 | 1.53% |
3 Month | 43.40% | 43.60% | 2.99 | 3.51% |
6 Month | 92.18% | 91.95% | 14.26 | 15.85% |
1 Year | 76.01% | 76.36% | 16.70 | 16.77% |
3 Year | 413.13% | 410.86% | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
22-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 153667 | 337.66 |
22-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 153667 | 338.02 |
22-07-2021 | XTX MARKETS LLP | NSE | SELL | 133405 | 338.09 |
22-07-2021 | XTX MARKETS LLP | NSE | BUY | 125571 | 338.22 |
20-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 159809 | 326.64 |
20-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 159809 | 326.66 |
20-07-2021 | XTX MARKETS LLP | NSE | BUY | 137824 | 325.64 |
20-07-2021 | XTX MARKETS LLP | NSE | SELL | 134085 | 326.46 |
09-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 280537 | 316.01 |
09-07-2021 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 280537 | 315.89 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 37.23 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 2.72 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 1.48 |
Other Institutional Investors | 0.65 |
Indian Public | 24.60 |
Others Non Institutional Investors | 33.32 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Executive Chairman : S P Vasireddi
Director (Operation) : V Harriman
Managing Director : Harita Vasireddi
Non-Exec. & Independent Dir. : Y Prameela Rani
Company Sec. & Compli. Officer : Sujani Vasireddi
Non-Exec. & Independent Dir. : G Purnachandra Rao
Non-Exec. & Independent Dir. : Sanjay Dave
Executive Director : Satya Sreenivas Neerukonda
Non-Exec. & Independent Dir. : Yadagiri R Pendri
Registered Office: Plot No 141/2 & 142, IDA Phase II Cherlapally,Hyderabad,Telangana-500051 Ph: 91-40-27264141
Email:shares@vimta.com